Testing effectiveness (Phase 2)WithdrawnNCT06331598
What this trial is testing
Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
Who this might be right for
Solid Tumors
Hoffmann-La Roche